An audit of antiemetic use with CMF chemotherapy

Clinical Oncology

Volumn 10, Issue 5, 1998, Pages 313-317

  Brown, R S D ^a,b   Brown, T K ^a   Hoare, D ^a   Gaze, M N ^a  

^a MIDDLESEX HOSPITAL   (United Kingdom)

^b MOUNT VERNON HOSPITAL   (United Kingdom)

Author keywords

5 hydroxytryptamine antagonist; Audit; CMF chemotherapy; Dexamethasone; Metoclopramide

Indexed keywords

ANTIEMETIC AGENT; CYCLOPHOSPHAMIDE; DEXAMETHASONE; FLUOROURACIL; GRANISETRON; METHOTREXATE; METOCLOPRAMIDE; SEROTONIN ANTAGONIST;

ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG COST; DRUG EFFICACY; HUMAN; MAJOR CLINICAL STUDY; MEDICAL AUDIT; NAUSEA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; VOMITING;

EID: 0031794927     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0936-6555(98)80085-X     Document Type: Article

References (17)

1. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31000 recurrences and 24000 deaths among 75000 women. Lancet 1992;339:1-15, 71-85.
2. Clavel M, Soukop M, Greenstreet YLA. Improved control of emesis and quality of life with ondansetron in breast cancer. Oncology 1993;50:180-5.
3. Barrenetxea G, Schneider J, Mae Centano M, et al. Chemotherapy induced emesis: management of early and delayed emesis in milder emetogenic regimens. Cancer Chemother Pharmacol 1996;38:471-5.
4. Stewart A. Optimal control of cyclophosphamide-induced emesis. Oncology 1996;53(Suppl 1):32-8.
5. Levitt M, Warr D, Yelle L, et al. Ondansetron compared with dexamethasone and metoclopramide in the chemotherapy of breast cancer with cyclophosphamide, methotrexate, and fluorouracil. N Engl J Med 1993;328:1081-4.
6. Bonadonna G, Rossi A, Valagussa P, et al. The CMF program for operable breast cancer with positive axillary nodes. Updated analysis on the disease-free interval, site of relapse and drug tolerance. Cancer 1977;39(6 Suppl):2904-15.
7. Secretary of State for Health, Wales, Northern Ireland and Scotland. Working for patients. HMSO, London, 1989:39.
8. Department of Health. The evolution of clinical audit. Leeds: DoH/National Health Service Executive.
9. US Department of Health and Human Services, Public Health Service, Agency for Healthcare Policy and Research. Acute pain management: operative or medical procedures and trauma. Rockville, MD: Agency for Healthcare Policy and Research, 1992.
10. Smyth JF, Coleman RE, Nicolson M, et al. Does dexamethasone enhance control of acute cisplatin-induced emesis by ondansetron? BMJ 1991;303:1423-6.
11. Roila F, Tonato M, Cognetti F, et al. Prevention of cisplatin-induced emesis: a double blind multicentre randomised crossover study comparing ondansetron and ondansetron plus dexamethasone. J Clin Oncol 1991;9:675-8.
12. Smith DB, Newlands ES, Rustin GJ, et al. Comparison of ondansetron and ondansetron plus dexamethasone as antiemetic prophylaxis during asplatin-containing chemotherapy. Lancet 1991; 338:487-90.
13. Beck TM. Efficacy of ondansetron tablets in the management of chemotherapy-induced emesis: review of clinical trials. Semin Oncol 1992;19(6 suppl 15):20-5.
14. 3 antagonist? Lancet 1992;340:1107-8.
15. Smith IE. A dose finding study of granisetron, a novel antiemetic, in patients receiving cytostatic chemotherapy. J Cancer Res Clin Oncol 1993;119:350-4.
16. Kamanabrou D. Intravenous granisetron - establishing the optimal dose. Eur J Cancer 1992;28A(Suppl 1):S6-S11.
17. Lemerle J, Amaral D, Southall DP, et al. Efficacy and safety of granisetron in the prevention of chemotherapy induced emesis in paediatric patients. Eur J Cancer 1991;27:1081-3.